You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

Claims for Patent: 10,376,578

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,376,578

Title:	Compositions and methods for treating Crohn\'s disease and related conditions and infections
Abstract:	In alternative embodiments, the invention provides a \"triple combination\" therapy for treating, ameliorating and preventing Crohn\'s Disease (or Crohn syndrome, terminal or distal ileitis or regional enteritis) or related disorders and conditions in mammals, such as paratuberculosis in mammals, or Johne\'s disease, including genetically-predisposed and chronic disorders, where the microbial or bacterial flora of the bowel is at least one causative or symptom-producing factor; and compositions for practicing same. In alternative embodiments, methods and compositions of the invention comprise or comprise use of therapies, medications, formulations and pharmaceuticals comprising active agents that can suppress or eradicate the microbiota super-infection that causes Crohn\'s Disease or paratuberculosis infection in mammals. In alternative embodiments, the methods and uses of the invention for treating, ameliorating and preventing Crohn\'s Disease and complications of Crohn\'s Disease, or related disorders and conditions in mammals, such as paratuberculosis in mammals, or Johne\'s disease, comprises administration to an individual (human or mammal) in need thereof: (1) an anti-TNF.alpha. composition, or a composition capable of down-modulating TNF.alpha. activity; (2) a Hyperbaric Oxygen Treatment, or HBOT; and (3) an anti-Mycobacterium avium sub species paratuberculosis (MAP) (an anti-MAP) agent, composition or therapy.
Inventor(s):	Agrawal; Gaurav (Manly, AU)
Assignee:	Agrawal; Guarav (Manly, AU)
Application Number:	15/483,702
Patent Claims:	1. A therapeutic combination for treating or ameliorating: a Crohn's Disease, or a complication of a Crohn's Disease, comprising: (1) an anti-TNF.alpha. agent, composition or drug, or an agent, a composition or a drug capable of down-modulating or down-regulating a TNF.alpha. activity; (2) an anti-Mycobacterium avium sub species paratuberculosis (MAP) (an anti-MAP) agent, composition, or drug; and (3) hyperbaric oxygen. 2. The a therapeutic combination of claim 1, wherein the anti-TNF.alpha. agent, composition or drug, or the agent, composition or drug capable of down-modulating or down-regulating a TNF.alpha. activity, comprises: infliximab; adalimumab; certolizumab, golimumab; basiliximab; daclizumab; omalizumab; or, any combination thereof. 3. The therapeutic combination of claim 1, wherein the anti-MAP agent, composition, or drug comprises rifabutin or clarithromycin. 4. The therapeutic combination of claim 1, comprising a combination of rifabutin and clarithromycin. 5. The therapeutic combination of claim 1, wherein the Crohn's Disease is a fistulising Crohn's Disease, or a complication of a fistulising Crohn's Disease, or a Crohn's Disease-related fistulae.

Details for Patent 10,376,578

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Hoffmann-la Roche Inc.	ZENAPAX	daclizumab	Injection	103749	12/10/1997	⤷ Try a Trial	2032-06-04
Novartis Pharmaceuticals Corporation	SIMULECT	basiliximab	For Injection	103764	05/12/1998	⤷ Try a Trial	2032-06-04
Novartis Pharmaceuticals Corporation	SIMULECT	basiliximab	For Injection	103764	01/02/2003	⤷ Try a Trial	2032-06-04
Janssen Biotech, Inc.	REMICADE	infliximab	For Injection	103772	08/24/1998	⤷ Try a Trial	2032-06-04
Genentech, Inc.	XOLAIR	omalizumab	For Injection	103976	06/20/2003	⤷ Try a Trial	2032-06-04
Genentech, Inc.	XOLAIR	omalizumab	Injection	103976	09/28/2018	⤷ Try a Trial	2032-06-04
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	12/31/2002	⤷ Try a Trial	2032-06-04
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.